^
Association details:
| Biomarker: | TNFA-L |
|---|---|
| Cancer: | Melanoma |
| Drug: | Clevegen (bexmarilimab) (STAB1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Low baseline serum IFNg and TNFa are predictive of response to bexmarilimab
Published date:
03/09/2022
Excerpt:
30 patients, 10 per each tumor type, were treated with bexmarilimab...At baseline, patients that saw a clinical benefit (CBR) from bexmarilimab had average serum IFNg levels of 5.11 pg/ml (SD, +/- 4.99 pg/ml) compared to 13.07 pg/ml (SD, +/- 13.26) in patients that did not respond to the treatment. Similarly serum TNFa levels 0.96 pg/ml (SD, +/- 0.74 pg/ml) in patients that benefited from bexmarilimab compared to 2.37 pg/ml (SD, +/- 1.43 pg/ml) in patients that did not respond to the treatment...Bexmarilimab works well in patients with low IFNg and TNFa levels...
